The introduction of UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium) reflects a key milestone for the brand. A landmark, 4-year global trial in chronic obstructive pulmonary disease (COPD), UPLIFT® is evaluating the potential of tiotropium to slow disease progression by reducing the rate of decline in lung function.
UPLIFT® Overview
| Duration: | 4 years |
|---|---|
| Results available: | 5 Oct 2008 |
| Clinical outcome: |
|
| Lead investigators: | Professor Marc Decramer Professor of Medicine, Catholic University Leuven, Belgium Professor Donald Tashkin Medical Director of Pulmonary Function Laboratory, University of California; Los Angeles, USA Dr Bartholme R Celli Professor of Medicine, Tufts University Boston Massachusetts, USA |
Sponsored by Boehringer Ingelheim and Pfizer Inc., UPLIFT® is assessing the long-term effects of tiotropium on lung-function decline, health-related quality of life, exacerbations and associated hospitalisations and mortality (respiratory and all-cause). A post-hoc analysis of data from two 1-year studies showed that patients had a rate of decline in lung function parameter through FEV1 of 12 ml/year compared with 58 ml/year for placebo, thus positively supporting the scientific rationale underlying UPLIFT®.
